| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 6636 | 2017 |
| Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014 | 5165 | 2014 |
| Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas Y Jiao, PJ Killela, ZJ Reitman, BA Rasheed, CM Heaphy, RF De Wilde, ... Oncotarget 3 (7), 709, 2012 | 712 | 2012 |
| Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord Y Wang, S Springer, M Zhang, KW McMahon, I Kinde, L Dobbyn, J Ptak, ... Proceedings of the National Academy of Sciences 112 (31), 9704-9709, 2015 | 482 | 2015 |
| A multiprotein supercomplex controlling oncogenic signalling in lymphoma JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ... Nature 560 (7718), 387-391, 2018 | 411 | 2018 |
| Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology LB Nabors, J Portnow, M Ahluwalia, J Baehring, H Brem, S Brem, ... Journal of the National Comprehensive Cancer Network 18 (11), 1537-1570, 2020 | 406 | 2020 |
| Vorasidenib in IDH1-or IDH2-mutant low-grade glioma IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... New England Journal of Medicine 389 (7), 589-601, 2023 | 368 | 2023 |
| NCCN guidelines insights: central nervous system cancers, version 1.2017 LB Nabors, J Portnow, M Ammirati, J Baehring, H Brem, N Butowski, ... Journal of the National Comprehensive Cancer Network 15 (11), 1331-1345, 2017 | 309* | 2017 |
| Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma IK Mellinghoff, BM Ellingson, M Touat, E Maher, MI De La Fuente, ... Journal of Clinical Oncology 38 (29), 3398-3406, 2020 | 275 | 2020 |
| First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma J Rodon, MA Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ... Clinical Cancer Research 21 (3), 553-560, 2015 | 255 | 2015 |
| Systemic use of tumor necrosis factor alpha as an anticancer agent NJ Roberts, S Zhou, LA Diaz Jr, M Holdhoff Oncotarget 2 (10), 739, 2011 | 222 | 2011 |
| High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma M Holdhoff, P Ambady, A Abdelaziz, G Sarai, D Bonekamp, J Blakeley, ... Neurology 83 (3), 235-239, 2014 | 170 | 2014 |
| Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: a validation study with image-guided stereotactic biopsy S Jiang, CG Eberhart, M Lim, HY Heo, Y Zhang, L Blair, Z Wen, ... Clinical Cancer Research 25 (2), 552-561, 2019 | 156 | 2019 |
| NCCN guidelines® insights: central nervous system cancers, version 2.2022: featured updates to the NCCN guidelines C Horbinski, LB Nabors, J Portnow, J Baehring, A Bhatia, O Bloch, S Brem, ... Journal of the National Comprehensive Cancer Network 21 (1), 12-20, 2023 | 132 | 2023 |
| Central nervous system cancers, version 1.2015 LB Nabors, J Portnow, M Ammirati, J Baehring, H Brem, P Brown, ... Journal of the National Comprehensive Cancer Network 13 (10), 1191-1202, 2015 | 126 | 2015 |
| Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced … J Rodón, M Carducci, JM Sepulveda-Sánchez, A Azaro, E Calvo, ... Investigational new drugs 33, 357-370, 2015 | 122 | 2015 |
| Central nervous system cancers LB Nabors, M Ammirati, PJ Bierman, H Brem, N Butowski, ... Journal of the National Comprehensive Cancer Network 11 (9), 1114-1151, 2013 | 116 | 2013 |
| Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations M Holdhoff, K Schmidt, R Donehower, LA Diaz JNCI: Journal of the National Cancer Institute 101 (18), 1284-1285, 2009 | 115 | 2009 |
| MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas N Nayyar, MD White, CM Gill, M Lastrapes, M Bertalan, A Kaplan, ... Blood advances 3 (3), 375-383, 2019 | 112 | 2019 |
| Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas KC Schreck, S Ranjan, N Skorupan, C Bettegowda, CG Eberhart, ... Journal of neuro-oncology 143, 87-93, 2019 | 110 | 2019 |